Growth Hormone and Performance Research Protocols

Two receptor families dominate this class. GHRH analogs bind the growth hormone releasing hormone receptor and increase the amplitude of natural pulses. Ghrelin receptor agonists act at a separate receptor and increase pulse frequency while suppressing somatostatin tone.

Because the two act on different receptors, they are frequently studied together. The combination produces a larger release than either alone, which is the reason combined GHRH and ghrelin agonist products exist as single vials.

Downstream, the measurable endpoint in most studies is IGF-1 rather than growth hormone itself, since GH is released in short pulses and a single serum reading tells you very little.

The pulsatile framing is the key difference between secretagogue research and direct administration of recombinant growth hormone. Secretagogues work through a pituitary that still responds to its own feedback loops, which is the stated reason many study designs prefer them when the research question concerns physiological signaling rather than maximal exposure.

Downstream, most of the measurable effect is mediated through IGF-1 produced in the liver in response to growth hormone. That is why IGF-1 concentration is the standard biomarker in these studies rather than growth hormone itself, whose pulsatile release makes a single point measurement close to meaningless.

Selectivity separates the compounds within this class. Some older secretagogues affect cortisol and prolactin alongside growth hormone, while the more selective ones do not, and that difference is usually the deciding factor in how a study protocol is constructed.

Performance endpoints in this literature are mixed. Body composition and recovery markers are reported more consistently than strength or power outcomes, so the compound pages state which endpoint each study actually measured.